Evidence map›Paper›PMID 26644020›Full record

ArticleProtein science : a publication of the Protein Society2016

Artificial domain duplication replicates evolutionary history of ketol-acid reductoisomerases.

Jackson K B Cahn, Sabine Brinkmann-Chen, Andrew R Buller, Frances H Arnold

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jackson K B CahnDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, 91125.
Sabine Brinkmann-ChenDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, 91125.
Andrew R BullerDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, 91125.
Frances H ArnoldDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, 91125.

Funding

Radical SAM enzyme engineering to produce improved thiopeptide antibioticsF32GM110851 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI BULLER, ANDREW · 2015 to 2016
$109k
NIGMS NIH HHS F32 GM110851
6 · The paper itself

Abstract

The duplication of protein structural domains has been proposed as a common mechanism for the generation of new protein folds. A particularly interesting case is the class II ketol-acid reductoisomerase (KARI), which putatively arose from an ancestral class I KARI by duplication of the C-terminal domain and corresponding loss of obligate dimerization. As a result, the class II enzymes acquired a deeply embedded figure-of-eight knot. To test this evolutionary hypothesis we constructed a novel class II KARI by duplicating the C-terminal domain of a hyperthermostable class I KARI. The new protein is monomeric, as confirmed by gel filtration and X-ray crystallography, and has the deeply knotted class II KARI fold. Surprisingly, its catalytic activity is nearly unchanged from the parent KARI. This provides strong evidence in support of domain duplication as the mechanism for the evolution of the class II KARI fold and demonstrates the ability of domain duplication to generate topological novelty in a function-neutral manner.

Indexed as

Gene DuplicationAmino Acid SequenceArchaeaCatalytic DomainCrystallography, X-RayKetol-Acid ReductoisomeraseModels, MolecularProtein FoldingProtein Structure, SecondaryKetol-Acid Reductoisomerasedomain duplicationfold evolutionketol-acid reductoisomeraseknotted proteins

Identifiers

PMID26644020
PMCPMC4918412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.